ReviewBreast cancer (Dove Medical Press)2015
Critical analysis of the potential for microRNA biomarkers in breast cancer management.
Review in Breast cancer (Dove Medical Press), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03895216 (Identification and Characterization of Predictive Factors of Onset of Bone Metastases in Cancer Patients), which is not on this map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Identification and Characterization of Predictive Factors of Onset of Bone Metastases in Cancer Patients
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Mindfulness-Based Stress Reduction on breast cancer symptoms: systematic review and meta-analysis.Einstein (Sao Paulo, Brazil) · 2018Pooled it
- Integrated roles of miR-125b, miR-375, and miR-451 in breast cancer chemoresistance: mechanistic insights and translational implications.Molecular biology reports · 2026Review
- Review
- microRNAs as Biomarkers of Breast Cancer.International journal of molecular sciences · 2025Review
- Exploring the Relationship between MicroRNAs, Intratumoral Microbiota, and Breast Cancer Progression in Patients with and without Metastasis.International journal of molecular sciences · 2024Article
- MicroRNA signatures differentiate types, grades, and stages of breast invasive ductal carcinoma (IDC): miRNA-target interacting signaling pathways.Cell communication and signaling : CCS · 2024Article
- Trials and Tribulations of MicroRNA Therapeutics.International journal of molecular sciences · 2024Review
- Complete characterization of RNA biomarker fingerprints using a multi-modal ATR-FTIR and SERS approach for label-free early breast cancer diagnosis.RSC advances · 2024Article
- Exosomal microRNAs in breast cancer: towards theranostic applications.Frontiers in molecular biosciences · 2024Review
- The effect of ribociclib on the expression levels of miR-141 and CDK4/6-USP51 signaling pathway genes in MCF-7 and MDA-MB-231 cells.PloS one · 2024Article
- Circulating microRNAs as Potential Biomarkers in Pancreatic Cancer-Advances and Challenges.International journal of molecular sciences · 2023Review
- Sauchinone inhibits breast cancer cell proliferation through regulating microRNA-148a-3p/HER-2 axis.Thoracic cancer · 2023Article
- Current and future applications of biomarkers in samples collected through minimally invasive methods for cancer medicine and population-based research.American journal of human biology : the official journal of the Human Biology Council · 2022Review
- Identification of differentially expressed microRNAs as potential biomarkers for carcinoma ex pleomorphic adenoma.Scientific reports · 2022Article
- A novel panel of blood-based microRNAs capable of discrimination between benign breast disease and breast cancer at early stages.RNA biology · 2021Article
- microRNA-based diagnostic and therapeutic applications in cancer medicine.Wiley interdisciplinary reviews. RNA · 2021Review
- Potential Prognostic Biomarkers of NIMA (Never in Mitosis, Gene A)-Related Kinase (NEK) Family Members in Breast Cancer.Journal of personalized medicine · 2021Article
- A New Look into Cancer-A Review on the Contribution of Vibrational Spectroscopy on Early Diagnosis and Surgery Guidance.Cancers · 2021Review
- Diversification of the CRISPR Toolbox: Applications of CRISPR-Cas Systems Beyond Genome Editing.The CRISPR journal · 2021Article
- The Role of Exosomes in Breast Cancer Diagnosis.Biomedicines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a complex and heterogeneous disease. Signaling by estrogen receptor (ER), progesterone receptor (PR), and/or human EGF-like receptor 2 (HER2) is a main driver in the development and progression of a large majority of breast tumors. Molecular characterization of primary tumors has identified major subtypes that correlate with ER/PR/HER2 status, and also subgroup divisions that indicate other molecular and cellular features of the tumors. While some of these research findings have been incorporated into clinical practice, several challenges remain to improve breast cancer management and patient survival, for which the integration of novel biomarkers into current practice should be beneficial. microRNAs (miRNAs) are a class of short non-coding regulatory RNAs with an etiological contribution to breast carcinogenesis. miRNA-based diagnostic and therapeutic applications are rapidly emerging as novel potential approaches to manage and treat breast cancer. Rapid technological development enables specific and sensitive detection of individual miRNAs or the entire miRNome in tissues, blood, and other biological specimens from breast cancer patients. This review focuses on recent miRNA research and its potential to address unmet clinical needs and challenges. The four sections presented discuss miRNA findings in the context of the following clinical challenges: biomarkers for early detection; prognostic and predictive biomarkers for treatment decisions using targeted therapies against ER and HER2; diagnostic and prognostic biomarkers for subgrouping of triple-negative breast cancer, for which there are currently no targeted therapies; and biomarkers for monitoring and characterization of metastatic breast cancer. The review concludes with a critical analysis of the current state of miRNA breast cancer research and the need for further studies using large patient cohorts under well-controlled conditions before considering the clinical implementation of miRNA biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.